This site is intended for US healthcare professionals only.

EFFICACY

Optune Pax with gem/nab-pac vs gem/nab-pac alone extended overall survival, delayed pain progression, and preserved quality of life longer.

Overall survival

Significantly extended overall survival in locally advanced pancreatic cancer1,2

Overall survival in the ITT population

68.1% 1-YEAR SURVIVAL RATE

with Optune Pax with gem/nab-pac (95% CI: 62.0, 73.5) vs 60.2% with gem/nab-pac (95% CI: 54.2, 65.7) 

Improved overall survival among patients who started and stayed on therapy for at least 1 full cycle1

Overall survival in the mPP population

75.2% 1-YEAR SURVIVAL RATE

with Optune Pax with gem/nab-pac (95% CI: 68.5, 80.7) vs 65.9% with gem/nab-pac (95% CI: 59.0, 72.0)

mPP population: Patients who received at least 1 cycle of gem/nab-pac (both arms) and, for the Optune Pax with gem/nab-pac arm, also received at least 4 weeks (28 days) of treatment with Optune Pax.

Pain endpoints

Delayed pain progression1,2

Time to pain progression

Patients treated with Optune Pax with gem/nab-pac lived a

MEDIAN OF 6.1 MONTHS LONGER, WITHOUT PAIN PROGRESSION1

Pain progression evaluated based on VAS score for pain

  • A common tool to measure overall pain intensity on a 0 to 100 scale3
  • Measured from randomization until a ≥20- point increase from baseline, a threshold representing the minimal clinically important difference for a meaningful change in pain intensity1
  • Analysis based on patient-reported outcomes1

Patients who experienced local disease progression were no longer followed for pain progression (67/285 patients in the Optune Pax with gem/nab-pac arm and 56/286 patients in the gem/nab-pac arm). Because a large number of patients stopped pain assessments after local disease progression, this censoring approach can lead to an overestimation.1

Delayed additional pain measures1,4

Additional predefined secondary pain endpoints

In a post hoc analysis, a trend of longer time to first use of opioid pain medication was observed in the Optune Pax with gem/nab-pac arm, compared to the gem/nab-pac arm1*

*Note that overall opioid medication exposure (in terms of types of frequency of exposure) was similar between the study arms.1

Patients who experienced local disease progression were not evaluated for quality of life endpoints following progression. Consequently, these results do not capture the quality of life status of patients with local disease progression. Notably, analyses that accounted for local disease progression showed consistent trends across the same QoL domains.1

Quality of life

Preserved quality of life longer1,4

Time to deterioration in global health status (GHS)

1.4 MONTH LONGER MEDIAN TIME TO DETERIORATION IN GLOBAL HEALTH STATUS

with Optune Pax with gem/nab-pac 7.1 months (95% CI: 5.7, 9.4) vs 5.7 months gem/nab-pac (95% CI: 4.1, 7.4)4*

  • Time to deterioration in GHS was measured from randomization until the first deterioration in GHS score of ≥10 points (on a 0 to 100 scale) based on the EORTC QLQ-C30 questionnaire4
  • Analysis based on patient-reported outcomes4

Extended time without deterioration in multiple digestive symptoms4

Time to deterioration in digestive symptoms

  • Time to deterioration in digestive symptoms was measured from randomization until the first deterioration in symptom score of ≥10 points (on a 0 to 100 scale) based on the EORTC QLQ-C30 questionnaire and PAN26 addendum4
  • Analysis based on patient-reported outcomes4

Patients who experienced local disease progression were not evaluated for quality of life endpoints following progression. Consequently, these results do not capture the quality of life status of patients with local disease progression. Notably, analyses that accounted for local disease progression showed consistent trends across the same QoL domains.1

The safety of Optune Pax was studied in the PANOVA-3 trial1

Review safety data

AE=adverse event; CI=confidence interval; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; gem/nab-pac=gemcitabine and nab-paclitaxel; HR=hazard ratio; ITT=intent-to-treat; mPP=modified per protocol; mOS=median overall survival; PAN26=pancreatic cancer–specific addendum to EORTC QLQ questionnaire; QoL=quality of life; TTD=time to deterioration; TTPP=time to pain progression; VAS=Visual Analog Scale.

 

 

 

References: 1. Optune Pax for Locally Advanced Pancreatic Cancer (LAPC). Physician Instructions for Use. Novocure; 2026 2. Babiker HM, Picozzi V, Chandana SR, et al. Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase III PANOVA-3 study. J Clin Oncol. 2025;43(21):2350-2360. doi:10.1200/JCO-25-00746 3. Åström M, Thet Lwin ZM, Teni FS, Burström K, Berg J. Use of the visual analogue scale for health state valuation: a scoping review. Qual Life Res. 2023;32(10):2719-2729. doi:10.1007/s11136-023-03411-3 4. Macarulla T, Picozzi V, Chandana S, et al. PANOVA-3: pain and quality of life outcomes with tumor treating fields (TTFields) therapy in patients with locally advanced pancreatic adenocarcinoma (LA-PAC). 2025 ESMO Gastrointestinal Cancers Annual Congress; July 2–5, 2025; Barcelona, Spain.

 

 

Indication for Use

Optune Pax® is intended for the treatment of adult patients with locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.

Important Safety Information

Contraindications

Do not use Optune Pax in patients with an electrical implant. Use of Optune Pax together with electrical implants has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Pax in patients with a known sensitivity to conductive hydrogels. In patients with this sensitivity, skin contact with the gel used with Optune Pax may commonly cause increased redness and itching. In rare cases, it may lead to severe allergic reactions that can cause a drop in blood pressure and difficulty breathing.

Warnings and Precautions

Optune Pax can only be prescribed by a healthcare provider who has completed the required certification training provided by Novocure® (the device manufacturer).

Do not prescribe Optune Pax for patients who are pregnant, who you think might be pregnant, or who are trying to get pregnant. Women who are able to get pregnant must use birth control when using the device. Safety and effectiveness of Optune Pax in these populations have not been established.

The most common (≥10%) adverse events involving Optune Pax concomitant with gemcitabine and nab-paclitaxel were neutropenia, anemia, thrombocytopenia, leukopenia, diarrhea, nausea, vomiting, abdominal pain, constipation, fatigue, peripheral edema, pyrexia, pain, COVID-19, infection, respiratory tract infection, urinary tract infection, pneumonia, hepatic enzyme increased, anorexia, hypokalemia, hypoalbuminemia, hyperglycemia, musculoskeletal pain, peripheral neuropathy, taste disorder, dizziness, sleep disorder, dyspnea, alopecia, skin-related disorders, and hypotension.

Optune Pax device-related skin adverse events (≥5%) include dermatitis, rash, pruritus, maculo-papular rash, erythema, skin irritation, skin reaction, and skin ulcer. Other device-related adverse effects associated with the use of Optune Pax include overheating of the array, leading to pain and/or local skin burns, allergic reaction to the adhesive or gel from the transducer arrays, and local warmth and tingling sensation beneath the arrays.

If the patient has an underlying skin condition on the abdomen, evaluate whether this may prevent or temporarily interfere with Optune Pax treatment.

Please see the Optune Pax Instructions for Use (IFU) for complete information regarding the device’s indication, contraindications, warnings, and precautions.

 

Indication for Use

Optune Pax® is intended for the treatment of adult patients with locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.

Important Safety Information

Contraindications

Do not use Optune Pax in patients with an electrical implant. Use of Optune Pax together with electrical implants has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Pax in patients with a known sensitivity to conductive hydrogels. In patients with this sensitivity, skin contact with the gel used with Optune Pax may commonly cause increased redness and itching. In rare cases, it may lead to severe allergic reactions that can cause a drop in blood pressure and difficulty breathing.

Warnings and Precautions

Optune Pax can only be prescribed by a healthcare provider who has completed the required certification training provided by Novocure® (the device manufacturer).

Do not prescribe Optune Pax for patients who are pregnant, who you think might be pregnant, or who are trying to get pregnant. Women who are able to get pregnant must use birth control when using the device. Safety and effectiveness of Optune Pax in these populations have not been established.

The most common (≥10%) adverse events involving Optune Pax concomitant with gemcitabine and nab-paclitaxel were neutropenia, anemia, thrombocytopenia, leukopenia, diarrhea, nausea, vomiting, abdominal pain, constipation, fatigue, peripheral edema, pyrexia, pain, COVID-19, infection, respiratory tract infection, urinary tract infection, pneumonia, hepatic enzyme increased, anorexia, hypokalemia, hypoalbuminemia, hyperglycemia, musculoskeletal pain, peripheral neuropathy, taste disorder, dizziness, sleep disorder, dyspnea, alopecia, skin-related disorders, and hypotension.

Optune Pax device-related skin adverse events (≥5%) include dermatitis, rash, pruritus, maculo-papular rash, erythema, skin irritation, skin reaction, and skin ulcer. Other device-related adverse effects associated with the use of Optune Pax include overheating of the array, leading to pain and/or local skin burns, allergic reaction to the adhesive or gel from the transducer arrays, and local warmth and tingling sensation beneath the arrays.

If the patient has an underlying skin condition on the abdomen, evaluate whether this may prevent or temporarily interfere with Optune Pax treatment.

Please see the Optune Pax Instructions for Use (IFU) for complete information regarding the device’s indication, contraindications, warnings, and precautions.

 

Novocure websites

This website is intended for US healthcare professionals seeking information on Optune Pax.

©2026 Novocure GmbH. All Rights Reserved.

Optune Gio, Optune Lua, Optune Pax, MyLink, MyNovocure, and Novocure are registered trademarks of Novocure GmbH.

All other trademarks, registered or unregistered, are the property of their respective owners.

US-OPP-00007 v1.0 March 2026